Oduro-Donkor, Dominic, Truner, Mark C., Farnaud, Sebastien, Renshaw, Derek, Kyrou, Ioannis, Hanson, Petra, Hattersley, John, Weickert, Martin O., Menon, Vinod, Randeva, Harpal S. and Barber, Thomas M. (2020) Modification of fecal microbiota as a mediator of effective weight loss and metabolic benefits following bariatric surgery. Expert Review in Endocrinology & Metabolism . doi:10.1080/17446651.2020.1801412 (In Press)

	PDF WRAP-Modification-faecal-microbiota-mediator-effective-weight-loss-Barber-2020.pdf - Accepted Version Embargoed item. Restricted access to Repository staff only until 24 July 2021. Contact author directly, specifying your specific needs. - Requires a PDF viewer. Download (1196Kb)
	Image (TIFF) WRAP-Expert Reviews Fig 1-Barber-2020.tif - Supplemental Material Embargoed item. Restricted access to Repository staff only until 24 July 2021. Contact author directly, specifying your specific needs. Download (916Kb)

Request Changes to record.

Abstract

Introduction
Bariatric surgery (primarily Laparoscopic Sleeve Gastrectomy [LSG] and Roux-en-Y Gastric Bypass [RYGB]) is an efficacious and durable therapeutic option for weight loss in obesity. The mechanisms that mediate weight loss following bariatric surgery remain incompletely understood.

Areas covered
Pubmed search of published data on fecal microbiota, metabolic health, LSG, and RYGB. The fecal microbiome plays a key role in the establishment and maintenance of metabolic wellbeing, and may also contribute (through fecal dysbiosis) to metabolic dysfunction. LSG and RYGB both result in characteristic, procedure-specific changes to the fecal microbiota that may mediate at least some of the resultant weight-loss and metabolically beneficial effects, when applied to the management of obesity.

Expert opinion
The human fecal microbiome, containing around 100 trillion microbes, evolved over millions of years and interacts symbiotically with its human host. Rodent-based studies have provided insights into the complexities of the gut-microbiome-brain axis. This includes the important role of the gut microbiome in the mediation of normal immunological development, inflammatory pathways, metabolic functioning, hypothalamic appetite regulation, and the absorption of essential nutrients as by-products of bacterial metabolism. Fecal transformation is likely to provide an important therapeutic target for future prevention and management of obesity and metabolic dysfunction.

Item Type:	Journal Article
Divisions:	Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine Faculty of Medicine > Warwick Medical School
Journal or Publication Title:	Expert Review in Endocrinology & Metabolism
Publisher:	Taylor & Francis
ISSN:	1744-6651
Official Date:	25 August 2020
Dates:	Date Event 25 August 2020 Published 24 July 2020 Available 22 July 2020 Accepted
Date of first compliant deposit:	24 July 2020
DOI:	10.1080/17446651.2020.1801412
Status:	Peer Reviewed
Publication Status:	In Press
Publisher Statement:	“This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review in Endocrinology & Metabolism on 24/07/2020, available online: http://www.tandfonline.com/10.1080/17446651.2020.1801412
Access rights to Published version:	Restricted or Subscription Access
Related URLs:	Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item